For years, a class of diabetes drugs has been quietly saving the lives of heart failure patients — reducing hospitalizations and deaths with a speed and consistency that medicine could not explain. Researchers at the University of Pennsylvania have now traced this quiet miracle to a single enzyme, PANK1, which these drugs activate in heart cells to unlock more efficient energy production. The discovery, published in Science, does not merely solve a biological puzzle; it opens a new chapter in how humanity might treat one of its most persistent and devastating conditions.